Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus

建立埃替米星(一种新型第四代氨基糖苷类抗生素)的流行病学临界值,该抗生素对大肠杆菌、肺炎克雷伯菌、奇异变形杆菌、铜绿假单胞菌、鲍曼不动杆菌和金黄色葡萄球菌有效。

阅读:2

Abstract

OBJECTIVE: To determine the epidemiological cut-off (ECOFF) values of etimicin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. METHODS: We selected 1500 isolates from five hospitals throughout five cities in China spanning from January 2018 to December 2021 in the study. Minimal inhibit concentrations (MICs) of etimicin were determined using the broth microdilution method. ECOFFs of etimicin against six species were calculated using ECOFFinder software and visual estimation following EUCAST principles. RESULTS: MICs of etimicin were distributed from 0.064 to >128 mg/L for S. aureus, from 0.125 to >128 mg/L for P. aeruginosa, from 0.25 to >128 mg/L for K. pneumoniae, P. mirabilis and A. baumannii, and from 0.5 to >128 mg/L for E. coli. The MIC ECOFF of etimicin was 2 mg/L for K. pneumoniae, 8 mg/L for E. coli and P. mirabilis, 16 mg/L for P. aeruginosa and A. baumannii, and the tentative ECOFF (TECOFF) of etimicin was 2 mg/L for S. aureus. CONCLUSIONS: (T)ECOFFs of etimicin against E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, A. baumannii and S. aureus were determined, which will be helpful to differentiate wild-type strains.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。